Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Lumara Health
October 04, 2016
Debt binge sees Aralez become a mini-Valeant
June 30, 2015
Amag moves into services with blood bank buy
February 13, 2014
Retrophin moves a step closer to becoming the new Questcor
July 22, 2013
Vivus won’t be fixed overnight, but here’s a plan
July 04, 2013
Japan continues to dominate small cap risers but US biotech muscles in
January 09, 2013
Sarepta joins the big league as best-performing 2012 share
October 10, 2012
Wockardt and Arena lead small-cap gainers through nine months
July 10, 2012
K-V Pharmaceutical orders a beer in last-chance saloon
January 18, 2012
Rough panel hearing could see Prochieve underachieve
April 04, 2011
Pharmasset the stand out small cap performer in first quarter
July 02, 2010
Mixed bag of small cap winners and losers in first half
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 27, 2021
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
April 22, 2021
Evaluate Vantage Report: US Approvals Under the Spotlight
Editor's Picks
June 07, 2021
Biogen makes history with Alzheimer’s approval
June 08, 2021
Biogen and the social contract
June 09, 2021
Asco 2021 story roundup
June 03, 2021
Asco 2021 justifies Novartis’s radioligand Vision
May 26, 2021
Roche remains big pharma’s biggest R&D spender
